Geron Stops IMpactMF After Survival Futility Review

Company Geron Event Type Phase 3 discontinuation (futility) Modality Telomerase-inhibiting oligonucleotide Asset Imetelstat (IMpactMF) Target Telomerase Disease Area JAK-inhibitor relapsed/refractory myelofibrosis Summary On 28 October Geron discontinued the 327-patient Phase III IMpactMF trial after its independent monitoring committee judged an overall-survival benefit unlikely in JAK-inhibitor…